Regulus Therapeutics reported $-8419000 in Operating Profit for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Alnylam Pharmaceuticals ALNY:US $ -181.68M 35.52M
Arena Pharmaceuticals ARNA:US $ -194.48M 50.09M
AstraZeneca AZN:LN -1674000000 2.8B
Astrazeneca AZN:US -1674000000 2.8B
Biogen BIIB:US $ 794M 308.3M
Celldex Therapeutics CLDX:US $ -20.82M 7.38M
Dicerna Pharmaceuticals DRNA:US $ -20.27M 19.97M
Gilead Sciences GILD:US $ 3842M 1596M
GlaxoSmithKline GSK:LN 1.94B 263M
Intercept Pharmaceuticals ICPT:US $ 10.29M 9.53M
Intrexon XON:US $ -25.47M 9.8M
Lexicon Pharmaceuticals LXRX:US -22962000 5M
Ligand Pharmaceuticals LGND:US $ 15.61M 27.83M
Merk MRK:US $ 4826M 3212M
Omeros OMER:US $ -18253000 5.76M
Regulus Therapeutics RGLS:US $ -8.42M 1.78M
Sangamo Biosciences SGMO:US $ -48.44M 0.26M
Spectrum Pharmaceuticals SPPI:US $ -33.09M 10.98M
Takeda 4502:JP Y 97427M 151125M
YTE INCY:US $ 235.41M 94.57M